Analysts Set Expectations for USNA FY2025 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at DA Davidson issued their FY2025 earnings estimates for USANA Health Sciences in a research report issued on Tuesday, February 25th. DA Davidson analyst C. Xue anticipates that the company will post earnings per share of $2.57 for the year. DA Davidson has a “Neutral” rating and a $36.00 price target on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. DA Davidson also issued estimates for USANA Health Sciences’ FY2026 earnings at $2.68 EPS.

Several other equities analysts have also recently commented on USNA. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Trading Down 14.0 %

Shares of NYSE USNA opened at $28.57 on Thursday. The stock has a fifty day simple moving average of $33.50 and a 200-day simple moving average of $36.56. USANA Health Sciences has a twelve month low of $27.71 and a twelve month high of $50.32. The stock has a market capitalization of $544.54 million, a PE ratio of 10.10, a PEG ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds have recently modified their holdings of USNA. R Squared Ltd purchased a new position in USANA Health Sciences during the 4th quarter worth $28,000. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences during the third quarter worth about $30,000. KBC Group NV raised its holdings in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in USANA Health Sciences in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP purchased a new stake in USANA Health Sciences in the 4th quarter valued at approximately $132,000. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.